Key result
Less frequent INR monitoring (≥2 days without measurement) was associated with higher odds of warfarin-associated adverse events in cardiac and surgical patients.
Why the study?
Does less frequent INR monitoring increase the risk of overanticoagulation and warfarin-related adverse events in hospitalized patients?
Cohort (n=8,529)
Yes
Does less frequent INR monitoring increase the risk of overanticoagulation and warfarin-related adverse events in hospitalized patients?
In hospitalized patients receiving warfarin, less frequent than daily INR monitoring is associated with an increased risk of overanticoagulation and warfarin-related adverse events.
Answers are grounded in this paper and cite their sources.
Infrequent INR monitoring may raise adverse event risk in hospitalized warfarin patients; leaves open whether daily monitoring improves outcomes in trials.
BACKGROUND: The optimum international normalized ratio (INR) monitoring frequency for hospitalized patients receiving warfarin is unknown. OBJECTIVE: Assess relationship between daily versus less frequent INR monitoring and overanticoagulation and warfarin-related adverse events. DESIGN: Retrospective cohort study using Medicare Patient Safety Monitoring System data. SETTING: Randomly selected acute care hospitals across the United States. PATIENTS: Patients hospitalized from 2009 to 2013 for pneumonia, acute cardiac disease, or surgery who received warfarin. INTERVENTIONS: None. MEASUREMENTS: (1) Association between frequency of INR monitoring and an INR ≥6.0 or warfarin-related adverse event. (2) Association between the rate of change of the INR and a subsequent INR ≥5.0 and ≥6.0. RESULTS: Among 8529 patients who received warfarin for ≥3 days, for 1549 (18.2%) the INR was not measured on 2 or more days. These patients had higher propensity-adjusted odds ratios (ORs) of having a warfarin-associated adverse event (OR: 1.48, 95% confidence interval [CI]: 1.02-2.17) for cardiac patients and surgical patients (OR: 1.73, 95% CI: 1.20-2.48), with no significant association for pneumonia patients. Cardiac and pneumonia patients with 1 day or more without an INR measurement had higher propensity-adjusted ORs of having an INR ≥6.0 (OR: 1.61, 95% CI: 1.07-2.41 and OR: 1.92, 95% CI: 1.36-2.71, respectively). A 1-day increase in the INR of ≥0.9 occurred in 621 patients (12.5%) and predicted a subsequent INR of ≥6.0 (positive likelihood ratio of 4.2). CONCLUSION: Daily INR measurement and recognition of a rapidly rising INR might decrease the frequency of warfarin-associated adverse events in hospitalized patients.
No takes yet. Share an insight, caveat, or question.
Metersky et al. (2015) conducted a cohort in Hospitalized patients receiving warfarin (n=8,529). Less frequent INR monitoring (not measured on ≥2 days) vs. Daily INR monitoring was evaluated on Warfarin-associated adverse event (cardiac patients) (OR 1.48, 95% CI 1.02-2.17). Less frequent INR monitoring (≥2 days without measurement) was associated with higher odds of warfarin-associated adverse events in cardiac and surgical patients.
Synapse has enriched 10 related papers. Consider them for comparative context: